Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators. (Q51738570)

11 April 2018

title

Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators. (English)

1 reference

11 April 2018

5

Peter Wipf

1 reference

11 April 2018

Manoj Kumar

1

1 reference

11 April 2018

Nicholas Reed

2

1 reference

11 April 2018

Ruiting Liu

3

1 reference

11 April 2018

Elias Aizenman

4

1 reference

11 April 2018

Thanos Tzounopoulos

6

1 reference

11 April 2018

publication date

22 March 2016

1 reference

11 April 2018

published in

Molecular Pharmacology

1 reference

11 April 2018

volume

89

1 reference

11 April 2018

issue

6

1 reference

11 April 2018

page(s)

667-677

1 reference

11 April 2018

Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97.

cites work

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Key factors in the discovery and development of new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

A potassium channel mutation in neonatal human epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Antiepileptic drug therapy the story so far

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Neural KCNQ (Kv7) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Characterization of a novel high-potency positive modulator of K(v)7 channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Utility of alkylaminoquinolinyl methanols as new antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

New tricks for old dogs: KCNQ expression and role in smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Kv7 channels as targets for anti-epileptic and psychiatric drug-development

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Structural insight into KCNQ (Kv7) channel assembly and channelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated Kv7.4 potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Expression, localization, and pharmacological role of Kv7 potassium channels in skeletal muscle proliferation, differentiation, and survival after myotoxic insults

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

The preclinical discovery and development of ezogabine for the treatment of epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Neuronal KCNQ potassium channels: physiology and role in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Atomic basis for therapeutic activation of neuronal potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of tinnitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Kv7 (KCNQ) channel modulators and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

KCNQ potassium channels: physiology, pathophysiology, and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

The Specific Slow Afterhyperpolarization Inhibitor UCL2077 Is a Subtype-Selective Blocker of the Epilepsy Associated KCNQ Channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

A bifunctional dimethylsulfoxide substitute enhances the aqueous solubility of small organic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Standards for epidemiologic studies and surveillance of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Kv7 channels as targets for the treatment of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Synthesis and biological evaluation of the first pentafluorosulfanyl analogs of mefloquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Voltage-gated potassium channels as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FMOL.115.103200

21 January 2018

Identifiers

DOI

10.1124/MOL.115.103200

1 reference

11 April 2018

1 reference

11 April 2018